PDS Biotechnology Crecimiento futuro
Future controles de criterios 0/6
Se prevé un crecimiento anual de los beneficios y los ingresos de PDS Biotechnology de 44.9% y 66% respectivamente, mientras que el BPA crecerá en un 48% al año.
Información clave
44.9%
Tasa de crecimiento de los beneficios
48.00%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 25.5% |
| Tasa de crecimiento de los ingresos | 66.0% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 13 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Amended Phase III Pathway And Long Patent Life Will Transform Future Cancer Care Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapy treatments for HPV16 positive cancers and other solid tumors. What are the underlying business or industry changes driving this perspective?
Regulatory And Financing Risks Around HPV Cancer Program Will Eventually Reward Patience
Catalysts About PDS Biotechnology PDS Biotechnology is a clinical stage company developing immunotherapy treatments for HPV16 positive cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?
HPV Positive Cancer Tailwinds And Trial Design Shifts Will Support Long Term Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapies for HPV16-positive head and neck cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Summary PDS Biotech is a clinical-stage company focused on developing immunotherapy-based approaches for cancer, with a focus on virus-driven tumors. Their main pipeline project is PDS0101, an immunotherapy targeting the p16 protein found in HPV16-infected cells in head and neck cancer. PDSB has shown promising clinical data, with a 74% 2-year overall survival rate in a phase 2 study, but their cash position is a concern. Read the full article on Seeking AlphaPDS Biotech jumps 13% as FDA clears further development of lead asset
PDS Biotechnology (NASDAQ:PDSB), a biopharma focused on cancer immunotherapies, added 13% pre-market Monday after the company announced that a recent End-of-Phase 2 meeting with the FDA brought clarity to the late-stage development of its lead asset PDS0101. At the meeting, PDSB has submitted interim data to indicate the potential of PDS0101 against a particular form of head and neck squamous cell carcinoma (HNSCC) in combination with Merck's (MRK) anti-PD-1 therapy, Keytruda. "The interim safety and efficacy data we presented to the FDA has allowed us to move into a registrational trial ahead of our projected schedule," Chief Executive Frank Bedu-Addo remarked. The FDA has issued Fast Track designation to PDS0101/ Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer.PDS Biotechnology files for $150 mixed shelf offering
PDS Biotechnology Corp. (NASDAQ:PDSB) has filed for a $150 mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for development and commercialization of product candidates and general corporate purposes. Separately, PDS Biotechnology (PDSB) said it entered into a debt financing agreement led by Horizon Technology Finance Corporation (HRZN) for up to $35M. Seeking Alpha's Quant Rating views PDS Biotechnology (PDSB) as a hold.PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
PDS Biotechnology (NASDAQ:PDSB) traded higher on Thursday after the biotech announced that an independent panel recommended its VERSATILE-002 trial for lead asset PDS0101 in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda be continued without changes. The decision of the independent Data Monitoring Committee (DMC) was based on safety data from the study which is designed to study PDS0101 and Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer. The DMC analysis of 43 patients indicated that there were no drug discontinuations related to toxicity or treatment related Grade 3 or greater adverse events, according to the company. In May, PDS Biotech (PDSB) announced that U.K. regulators accepted its application seeking to conduct the VERSATILE-002 trial in that country.PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or metastatic head and neck cancer patients. Proof of concept for PDS Biotechnology's Versamune T-cell activating technology platform was established. PDS Biotechnology had $58.9 million in cash as of March 31, 2022; enough cash to fund its operations into 2024.PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
PDS0101 could become the first line therapy in HPV-16 associated cancers (40,500 cases/year in the U.S. or $6 billion/year revenue opportunity). The company has an enterprise value of just $125M. The stock has near-term catalysts this year and is at a good buy level.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 2 | -35 | -46 | N/A | 2 |
| 12/31/2027 | N/A | -35 | -39 | N/A | 2 |
| 12/31/2026 | N/A | -31 | -30 | N/A | 2 |
| 3/31/2026 | N/A | -33 | N/A | N/A | N/A |
| 12/31/2025 | N/A | -34 | -28 | -28 | N/A |
| 9/30/2025 | N/A | -35 | -32 | -32 | N/A |
| 6/30/2025 | N/A | -37 | -34 | -34 | N/A |
| 3/31/2025 | N/A | -35 | -34 | -34 | N/A |
| 12/31/2024 | N/A | -38 | -35 | -35 | N/A |
| 9/30/2024 | N/A | -41 | -35 | -35 | N/A |
| 6/30/2024 | N/A | -41 | -34 | -34 | N/A |
| 3/31/2024 | N/A | -44 | -30 | -30 | N/A |
| 12/31/2023 | N/A | -43 | -34 | -34 | N/A |
| 9/30/2023 | N/A | -51 | -33 | -33 | N/A |
| 6/30/2023 | N/A | -48 | -31 | -31 | N/A |
| 3/31/2023 | N/A | -42 | -33 | -33 | N/A |
| 12/31/2022 | N/A | -41 | -26 | -26 | N/A |
| 9/30/2022 | N/A | -28 | -23 | -23 | N/A |
| 6/30/2022 | N/A | -28 | -22 | -22 | N/A |
| 3/31/2022 | N/A | -22 | -15 | -15 | N/A |
| 12/31/2021 | N/A | -17 | -12 | -12 | N/A |
| 9/30/2021 | N/A | -15 | -13 | -13 | N/A |
| 6/30/2021 | N/A | -12 | -9 | -9 | N/A |
| 3/31/2021 | N/A | -14 | -14 | -14 | N/A |
| 12/31/2020 | N/A | -15 | -13 | -13 | N/A |
| 9/30/2020 | N/A | -15 | -14 | -14 | N/A |
| 6/30/2020 | N/A | -17 | -17 | -17 | N/A |
| 3/31/2020 | N/A | -18 | -18 | -18 | N/A |
| 12/31/2019 | N/A | -7 | N/A | -18 | N/A |
| 9/30/2019 | N/A | -5 | N/A | -13 | N/A |
| 6/30/2019 | N/A | 0 | N/A | -9 | N/A |
| 3/31/2019 | N/A | 4 | N/A | -5 | N/A |
| 12/31/2018 | N/A | -4 | N/A | -2 | N/A |
| 9/30/2018 | N/A | -2 | N/A | -2 | N/A |
| 12/31/2017 | N/A | -3 | N/A | -3 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que PDSB siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que PDSB siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que PDSB siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que PDSB no tenga ingresos el año que viene.
Ingresos de alto crecimiento: Se prevé que PDSB no tenga ingresos el año que viene.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PDSB se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 20:00 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
PDS Biotechnology Corporation está cubierta por 5 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| James Molloy | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |